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Decline in circulating sex steroid hormones accompanies several age-associated pathologies which may influence
human healthspan. Mitochondria play important roles in biosynthesis of sex steroid hormones, and these hormones
can also regulate mitochondrial function. Understanding the cross talk between mitochondria and sex steroid
hormones may provide insights into the pathologies associated with aging. The aim of this review is to summarize
the current knowledge regarding the interplay between mitochondria and sex steroid hormones during the aging
process. The review describes the effect of mitochondria on sex steroid hormone production in the gonads, and
then enumerates the contribution of sex steroid hormones on mitochondrial function in hormone responsive cells.
Decline in sex steroid hormones and accumulation of mitochondrial damage may create a positive feedback loop
that contributes to the progressive degeneration in tissue function during aging. The review further speculates
whether regulation between mitochondrial function and sex steroid hormone action can potentially influence
healthspan.
Keywords: Mitochondrial damage, Estrogen, Progesterone, Testosterone, Longevity, Reproductive aging, Reactive
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Introduction
Sex steroid hormones play important roles in maintain-
ing normal reproductive and non-reproductive func-
tions. Because aging is accompanied by decreasing levels
of circulating sex steroid hormones (that is, estrogen,
progesterone, and testosterone) [1,2], many researchers
and clinicians had previously hypothesized that the de-
cline in these hormones promotes tissue degeneration
and age-related pathologies. As a result, hormone re-
placement therapies have already been used to alleviate
age-related symptoms in men and women. However, the
efficacy of these treatments remains debatable. Hence, it
is important to evaluate the contribution of sex steroid
hormones on healthspan.
Mitochondria regulate sex steroid hormone biosyn-
thesis, and sex steroid hormones are also implicated in
controlling mitochondrial function. This co-regulation
between mitochondria and sex steroid hormone signal-
ing is important for maintaining proper physiology.Correspondence: mvelarde@buckinstitute.org
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stated.Disrupting the crosstalk between mitochondrial function
and sex steroid hormone action may alter cellular re-
sponses and accelerate aging-associated phenotypes. Un-
derstanding the relationship between mitochondria and
sex steroid hormones may provide insights into the effi-
cacy of using hormone replacement therapies to treat
age-related diseases. This review summarizes the current
knowledge regarding the crosstalk between mitochon-
dria and sex steroid hormones during aging, and exam-
ines whether the interplay between mitochondrial
function and sex steroid hormone action can potentially
influence healthspan.Sex steroid hormones and aging
Sex steroid hormone production declines during
reproductive aging
Reproductive aging is defined as the gradual decline in
fertility during the aging process. It is accompanied by
decreasing levels of circulating sex steroid hormones es-
trogen, progesterone, and testosterone [1,2]. In women,
the end of reproductive aging occurs when ovarian folli-
cles drop below a threshold (approximately < 1,000 folli-
cles), resulting in cessation of the menstrual cycle whichThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ovarian follicle reserves begins to decline from birth as a
result of continuous maturation, ovulation, and atresia
[4]. Ovarian follicles eventually become exhausted by the
age of 51, which corresponds to the median age of
menopause in the general population [5]. Because granu-
losa cells and theca cells of the ovarian follicles are the
major sources of sex steroid biosynthesis in women, re-
productive aging eventually leads to reduced estrogen
and progesterone production [6], although the drop in
progesterone levels surpasses the drop in estrogen levels
during the menopausal transition [7].
In men, reproductive aging is accompanied by a de-
cline in the ability of the testes to produce testosterone
[8]. Leydig cells of the testes provide a significant source
of testosterone in males. Reduced number of Leydig
cells and decreased ability to respond to intracellular
signaling during aging may contribute to low testoster-
one levels in aging men [9-11]. Testosterone produc-
tion gradually decreases by approximately 1%–3% per
year, beginning around the age of 35–40 years [12],
and can eventually result in hypogonadism (<325 ng/dL
of total serum testosterone) in older men. Partial an-
drogen deficiency (sometimes referred as andropause)
occurs in ~20% of men by age 60 and ~50% of men by
age 80 [13].
Sex steroid hormone replacement may extend healthspan
but not lifespan
The decline in sex steroid hormones with age is thought to
reduce healthspan. In women, menopause correlates with
several age-related diseases, such as hot flashes, bone loss,
weight gain, vaginal atrophy, night sweats, sleep problems,
mood changes, and skin atrophy [14,15]. Estrogen replace-
ment alleviates some of these menopausal symptoms,
resulting in lowered frequency and severity of hot flashes,
decreased bone loss and vertebral fractures, and increased
bone mass [16]. Estrogen can also provide many beneficial
effects to skin physiology and protects against skin aging
[17]. In female mice, loss of sex steroid hormones by ovari-
ectomy also presents numerous age-related diseases similar
to those found in humans, such as accelerated bone loss,
decreased uterine weight, increased fat mass, and impaired
wound healing, which can all be alleviated by estrogen re-
placement [18-20].
Because estrogen increases the risk of endometrial can-
cers to women, progesterone supplements were added to
estrogen replacement therapies to inhibit the proliferative
effects of estrogen in the uterus. Estrogen plus progesterone
replacement therapy provides many beneficial effects simi-
lar to those of estrogen alone treatment, but it also seems
to increase the risk for other types of diseases, such as
breast cancer [16]. Findings from the Women’s Health Ini-
tiative show a high risk-to-benefit ratio of using hormonereplacement therapies. However, criticisms of the regimens
used suggest that health status or age at initiation of treat-
ment may contribute to severity of the side effects associ-
ated with hormone replacement therapy [21,22]. Analysis
of the current Kronos Early Estrogen Prevention Study
(KEEPS) [23] and the Early versus Late Intervention Trial
with Estradiol (ELITE) will hopefully address whether hor-
mone replacement therapy is beneficial within a critical
window of time [24,25].
In men, hypogonadism at old age is correlated with age-
related symptoms, such as impotence, decreased virility, de-
creased libido, and limited physical vigor [26]. However, it
remains debatable whether these age-related phenotypes
are mainly due to the decline in testosterone levels. In fact,
while testosterone replacement can alleviate some of the
aging characteristics associated with partial androgen defi-
ciency [27-31], testosterone supplementation in aged men
does not always seem to improve physical function [32].
Moreover, increased skeletal muscle mass due to testoster-
one does not seem to be specific to aged men [33]. In male
mice, testosterone can increase skeletal muscle regener-
ation [34], but it may also accelerate aging phenotypes in
other tissues, such as heart and kidneys [35]. Hence, the
overall impact of testosterone on healthspan needs further
investigation. The current Testosterone Trial will hopefully
address the benefit and risk of testosterone replacement in
hypogonadal men above the age of 65.
While sex steroid hormones may potentially extend
healthspan, the effect of sex steroid hormones on life-
span is less clear. For example, while increasing age at
menopause in women is associated with an overall in-
creased lifespan [36], menopausal age does not seem to
predict lifespan in non-human primates, as chimpanzees
rarely reach menopause whether in captivity or in the
wild [37,38]. Moreover, the length of postmenopausal
years (that is, period of reduced sex steroid hormones)
does not seem to be proportionally correlated with age
at death [39]. In males, castration in rats and dogs in-
creases lifespan [40,41]. However, while some studies
show that castration in humans (that is, eunuchs) ex-
tends lifespan [42,43], another report mentions no
change in lifespan [44]. Nevertheless, several studies
have linked reduced sex steroid hormones to many age-
related diseases. Hence, while loss of sex steroid hor-
mones may not significantly influence longevity and life-
span, reduced sex steroid hormones can potentially
shorten overall healthspan.
Mitochondria and sex steroid hormone
biosynthesis
Sex steroid hormone biogenesis
Mitochondria play an essential role during the initial
steps of sex steroid hormone biosynthesis, particularly
by producing the sex steroid hormone precursor
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the inner mitochondrial membrane is a rate limiting step
during the initial biosynthesis of sex steroid hormones
[45]. Cholesterol transport involves interaction between
the steroidogenic acute regulatory protein (StAR) and a
multi-component molecular complex, which is com-
posed of an 18 kDa translocator protein (TSPO), the
voltage dependent anion channel, TSPO-associated pro-
tein 7, and protein kinase A subunit 1a [46]. Once
imported, cholesterol is converted to pregnenolone by
the cytochrome P450 side-chain cleavage (P450scc; or
CYP11A1) enzyme, located on the inner membrane of
the mitochondria, involving the oxidation of nicotina-
mide adenine dinucleotide phosphate (NADPH) [47].
Pregnenolone can then be exported out of the mito-
chondria and converted by specific microsomal P450 en-
zymes into the different sex steroid hormones [48].
In males, testosterone biogenesis mostly occurs in
Leydig cells through the sequential conversion of
pregnenolone to 17α-hydroxypregnenolone, dehydro-
epiandrosterone (DHEA), androstenedione, and testos-
terone [47]. In females, however, estrogen and
progesterone biosynthesis occurs through the cross-
talk between the granulosa and theca cells of the
ovarian follicle. Pregnenolone in granulosa cells can
diffuse to theca cells and be converted into andro-
stenedione, which then re-diffuses back to granulosa
cells and is eventually processed to estrogen. In some
instances, androstenedione produced by the theca
cells can also be immediately converted to testoster-
one in these cells. During the luteal phase of the
menstrual cycle, progesterone is produced in lutein-
ized granulosa cells by direct conversion from
pregnenolone.
Mitochondrial damage may promote menopause and
partial androgen deficiency
Mitochondria can produce reactive oxygen species (ROS)
at multiple sites of the electron transport chain [49]. During
mitochondrial respiration, the electron transport chain gen-
erates a flux of electrons, capable of establishing a proton
gradient within the mitochondria. While this proton gradi-
ent is necessary for ATP production, electrons produced
during oxidative phosphorylation need to be completely
neutralized to water upon reaction with oxygen at complex
IV (that is, cytochrome c oxidase). However, partial reduc-
tion of oxygen can occur upstream of complex IV, resulting
in production of superoxides. These superoxides are nor-
mally eliminated by antioxidants (that is, superoxide dismu-
tases, SOD) in the mitochondria. However, in certain
conditions, some superoxides are thought to escape the
mitochondrial antioxidant system and cause damage to
mitochondrial proteins and DNA. Damaged mitochondria
become less efficient in transferring electrons across therespiratory chain, rendering more electrons to be converted
to superoxides. This positive feedback loop of mitochon-
drial superoxide (ROS) production and mitochondrial dam-
age was proposed to cause aging, a theory known as the
free radical theory of aging [50,51]. Consistent with this
theory, damage to mitochondrial DNA, lipids, and proteins
increases with age, and is accompanied by decreased mito-
chondrial membrane potential and impaired mitochondrial
function [52,53].
In women, drop in sex steroid hormones during
menopause is mainly attributed to loss of ovarian folli-
cles. Continuous ovulation and follicular atresia, plus in-
ability of follicles to naturally regenerate, eventually lead
to reduced sex steroid hormone production. Aside from
this progressive decline in follicle numbers, it is sug-
gested that excessive oxidative damage in the ovaries,
due to a decrease in the levels of antioxidants, may be a
potential contributing factor for reproductive aging [54].
While it is yet to be shown whether mitochondrial ROS
generation promotes mitochondrial damage in ovarian
follicles, increased number of damaged mitochondria
have been observed in ovarian follicles of aged women
[55,56] and the proportion of granulosa cells with rup-
tured mitochondrial membranes significantly increase
with age [55]. While human studies only reveal correla-
tions between mitochondrial damage and loss of ovarian
follicles, mouse studies show that mitochondrial damage
can contribute to reproductive aging. Mitochondrial
DNA damage in a mouse model with defective mito-
chondrial DNA polymerase can reduce female fertility
[57]. Mitochondrial dysfunction in a mouse model with
high mitochondrial ROS generation also results in infer-
tility, defective folliculogenesis, and impaired ovulation
[58]. Hence, mitochondrial damage may potentially ac-
celerate the decline in ovarian follicles and partly con-
tribute to reproductive aging in females.
In men, drop of testosterone levels during aging is as-
sociated with decreasing supply of mitochondrial steroid
precursors by Leydig cells [9,10]. In male rats, testoster-
one levels have also been shown to decline with age [59].
This age-related decline in testosterone steroidogenesis
is consistent with decreased mitochondrial expression of
StAR and CYP11A1 in Leydig cells of old versus young
rats [60]. While the cause of this decline in StAR and
CYP11A1 expression is still unclear, it has been pro-
posed that ROS may contribute to this effect. Increased
mitochondrial ROS was observed in Leydig cells of old
versus young rats [61]. Transient elevation of ROS pro-
duction after luteinizing hormone treatment caused
more DNA damage in aged versus young Leydig cells
[62]. Moreover, ROS (that is, H2O2) can inhibit testoster-
one biosynthesis in the mouse Leydig cell line MA-10
and a primary rat Leydig cell line [63,64]. But because
the concentration used is relatively high (100 to 250
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to steroidogenesis remains questionable. Nevertheless,
while the biological impact of mitochondrial ROS on
steroidogenesis needs further validation, the role of
mitochondria in producing steroid precursors suggests
that properly functioning mitochondria are important to
maintain sex steroid hormone levels. Hence, there is a
need to critically evaluate the contribution of mitochon-
drial damage on sex steroid hormone production during
aging.
Sex steroid hormones and mitochondrial function
Sex steroid hormone nuclear receptors regulate
mitochondrial gene expression
While mitochondria mediate sex steroid hormone produc-
tion, sex steroid hormones can also regulate mitochondrial
function. Sex steroid hormones estrogen, progesterone, and
testosterone classically function by binding to their nuclear
receptors: estrogen receptors (ERα and ERβ1-6), progester-
one receptors (PR-A and PR-B), and androgen receptors
(AR1 and AR2), respectively. These receptors along withFigure 1 Molecular targets of estrogen in regulating mitochondrial fu
to directly regulate tissue-specific expression of genes necessary for cellula
mitochondrial genes by promoting gene expression of transcription factor
binds to membrane ERs and activates signaling cascades that protect mito
ERs and limits ROS generation in the mitochondria. 5. Estrogen binds to m
mitochondrial genes.specific nuclear receptor co-regulators can directly or indir-
ectly bind to nuclear DNA regulatory elements and influ-
ence gene expression [65]. While the direct contributions
of testosterone and progesterone on mitochondrial function
are less studied, the effect of estrogen on mitochondrial
function and biosynthesis is more evident. Estrogen,
through its receptor, can directly modulate expression of
genes important for mitochondrial function (Figure 1). Es-
trogen can directly up-regulate transcription of nuclear re-
spiratory factor-1 (NRF1), a key transcription factor
necessary for regulating expression of most of the mito-
chondrial respiratory chain complex proteins [66]. NRF1
promoter contains putative estrogen receptor response ele-
ments capable of binding both ERs [66,67]. ERα can also
interact with peroxisome proliferator-activated receptor
gamma coactivator 1 (PGC-1), another important tran-
scription factor that promotes transcription of NRFs and
other mitochondrial proteins [68]. Regulation of NRFs and
PGC-1 by estrogen is thought to play an important role
in modulating overall mitochondrial biogenesis and func-
tion [69].nction. 1. Estrogen binds to nuclear estrogen receptors (ERα and ERβ)
r function. 2. Estrogen binds to nuclear ERs and regulates expression of
NRF1 and enhancing transcriptional activity of PGC1α. 3. Estrogen
chondria from oxidative damage. 4. Estrogen binds to mitochondrial
itochondrial ERs and regulates transcription of mitochondrial-encoded
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mitochondrial oxidative damage
Aside from the function of sex steroid hormones in the
nucleus, sex steroid hormones can also have rapid, nonge-
nomic actions by activating plasma membrane-associated
receptors, leading to intracellular protein kinase-mediated
phosphorylation signaling cascades [70]. While studies re-
garding the contribution of plasma membrane-associated
receptors on mitochondrial function are very limited, some
reports suggest a role for this signaling in mitochondria.
Estrogen, by acting on plasma membrane-associated ER, is
thought to trigger a phosphorylation cascade and limit
mitochondrial oxidative damage (Figure 1). One of the early
studies suggesting this phenomenon was when a BSA-
conjugated form of estrogen, which is membrane-
impermeable, was able to undergo rapid internalization and
translocation into mitochondria but not the nucleus
[71,72]. Estrogen, acting through intracellular phosphoryl-
ation cascades, may protect mitochondria from oxidative
damage. One study shows that estrogen can activate the
MAP kinase and NF-kB pathways to reduce cellular levels
of hydrogen peroxides by stimulating the nuclear transcrip-
tion of mitochondrial antioxidant enzyme Sod2 [73]. How-
ever, it remains to be confirmed whether this estrogen-
mediated Sod2 mRNA regulation is necessary to protect
against mitochondrial oxidative damage. Another study also
shows that estrogen can activate ERK, permit its transloca-
tion to the mitochondria, and enhance cytochrome c
oxidase complex IV activity [74]. Whether these estrogen
actions are due to plasma membrane-associated receptors
and whether they play a significant role in protecting
mitochondria against oxidative damage needs further
investigation.
Mitochondria-associated sex steroid hormone receptors
protect against mitochondrial oxidative damage
Sex steroid hormone receptors, particularly ERs, have
been observed to localize in mitochondria and contrib-
ute to mitochondrial function (Figure 1). Despite the
controversy regarding mitochondrial localization of ERs
[75,76], accumulating evidence suggest that both ERα
and ERβ are indeed present in the mitochondria, de-
pending on cell type [77-80]. ERβ seems to be the ER
that is more frequently present in mitochondria of most
cell types [81-85]. Knockdown of the ERβ1 isoform,
which predominantly localizes to mitochondria, elimi-
nates estrogen-dependent protection against peroxide-
induced mitochondrial membrane depolarization [86].
Using a targeting vector containing mitochondrial or nu-
clear localization sequences, ER can be efficiently tar-
geted to mitochondria or nucleus [84]. Expression of a
mitochondrial-targeted, but not a nuclear-targeted ER,
confers estrogen-dependent inhibition of UV-induced
mitochondrial depolarization in a breast cancer cell lineMCF-7 by enhancing mitochondrial SOD2 protein activ-
ity, independent of its transcriptional regulation [84].
However, the mechanism of ER in regulating SOD2
protein activity remains unclear and needs further
confirmation.
Sex steroid hormone receptors in the mitochondria
can regulate transcription of mitochondrial encoded
genes [87]. Mitochondrial DNA contains hormone re-
sponse elements, which allow binding of steroid hor-
mone receptors. Indeed, ER in the mitochondria can
bind to estrogen response elements (ERE) located
in mitochondrial DNA (Figure 1) [88]. This estrogen-
mediated ER binding to mitochondrial DNA is thought
to increase expression of mitochondrial-encoded mito-
chondrial genes associated with the electron transport
chain [89]. Aside from regulating transcription of
mitochondrial encoded genes, sex steroid hormone re-
ceptors have been suggested to bind to mitochondrial
proteins. For example, ERβ has been shown to co-
immunoprecipitate with the mitochondrial protein ATP
synthase [90]. However, whether this interaction is func-
tional remains to be addressed.
Hormone replacements improve mitochondrial function
in healthy cells
Estrogen can inhibit mitochondrial ROS generation in
primary cells, such as endothelial cells, cardiomyocytes,
and epithelial lens cells [86,91-93]. Animal experiments
also demonstrate that estrogen can reduce mitochondrial
ROS production and enhance mitochondrial respiration
in normal brains of male and female rats [94,95]. Estro-
gen seems to limit mitochondrial ROS production in cell
types, which are predominantly expressing ERβ, but a
few studies have also supported a protective role of ERα
[96].
While estrogen replacement seems to provide overall
beneficial effects on mitochondrial function, timing of
treatment and type of cell may be important for this
phenomenon. Estrogen can decrease mitochondrial ROS
production in non-cancer primary cells, but it can
also increase ROS production in damaged estrogen-
responsive cancer cells [97-99]. This suggests that while es-
trogen can protect normal cells from oxidative stress, it ex-
acerbates oxidative stress in damaged cells, that is, cancer
cells. While it remains unclear what mechanisms regulate
this contradictory effect of estrogen on mitochondrial ROS
production, the contribution of damaged versus healthy cell
on estrogen action is consistent with the critical window
and healthy cell hypothesis of estrogen replacement therapy
[22,100]. This hypothesis proposes that estrogen replace-
ment is only beneficial if performed at the appropriate time
of a woman’s life, before she accumulates a certain thresh-
old of cellular damage. Indeed, estrogen replacement ther-
apies seem to be more beneficial in younger versus older
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KEEPS and ELITE studies on estrogen replacement therap-
ies [23]. Results from these studies will hopefully address
some of these questions.
The effect of testosterone replacement on mitochondrial
function is less well understood. Low levels of testosterone
in males seem to be associated with reduced expression of
mitochondrial respiratory genes and activity [101]. Orchiec-
tomy in young male mice decreases expression of genes
associated with energy metabolism, oxidative phosphoryl-
ation, and ubiquinone pathways [102]. AR overexpression
in myocytes increases mitochondrial enzyme activities and
oxygen consumption [103,104]. Testosterone therapy po-
tentiates the effect of low-intensity physical training in old
male mice by increasing mitochondrial biogenesis, improv-
ing mitochondrial quality, and increasing spontaneous
physical activity, respiration, muscle mass, and grip strength
[105]. However, testosterone has also been shown to reduce
mitochondrial function [106]. Whether or not testosterone
play a major role in mitochondrial function needs further
investigation.
The positive feedback loop of mitochondrial
damage
Mitochondria play important roles in the biosynthesis of
sex steroid hormones by housing important enzymes forFigure 2 Mitochondria and sex steroid hormones during aging. Mitoc
conversion of cholesterol to pregnenolone. Sex steroid hormones improve
by regulating: 1. gene expression of nuclear-encoded mitochondrial protein
proteins, and/or 3. activity of mitochondrial proteins. Increased oxidative st
Decline in sex steroid hormone biosynthesis during aging compromises m
age-related pathologies.steroidogenesis and by maintaining cells that produce
these hormones (Figure 2). Conversely, sex steroid hor-
mones help to maintain mitochondrial function and
limit aging phenotypes. According to the free radical
theory of aging, mitochondrial ROS produced during
cellular respiration can result in mitochondrial damage,
which then initiates a positive feedback loop of increased
mitochondrial ROS generation and mitochondrial dam-
age with age. Accumulation of damaged mitochondria
can compromise steroidogenesis by damaging gonadal
cells, resulting in decreased sex steroid hormone levels.
Decline in sex steroid hormones exacerbates mitochon-
drial dysfunction and further promotes mitochondrial
damage. This cycle of mitochondrial damage and decline
in sex steroid hormone levels can potentially contribute
to the progressive degeneration in tissue function during
aging.
While the free radical theory provides a potential
model for the cause of aging, several studies have ques-
tioned whether accumulation of mitochondrial oxidative
damage actually drives the aging process [107,108].
Some studies support the theory [109,110], but others
suggest that increased mitochondrial ROS production
does not decrease lifespan [111], but can even potentially
extend lifespan [112]. It is possible that depending on
the amount and context, mitochondrial ROS productionhondria produce sex steroid hormones in the gonads through initial
and/or maintain mitochondrial function in hormone responsive cells
s, 2. gene expression of mitochondrial-encoded mitochondrial
ress during aging damages gonadal cells and/or impair steroidogenesis.
itochondrial function in hormone responsive tissues and contribute to
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mitochondrial ROS may result in cellular damage and
aging, but low mitochondrial ROS production may pro-
vide a hormetic effect that extends lifespan [113]. Fur-
ther research needs to be performed to confirm the
validity of the theory.
It is also important to note, that while this review
focused on the effects of sex steroid hormones on mito-
chondrial function, sex steroid hormones can also regu-
late other cell function independent of mitochondria
(Figure 1). Moreover, while estrogen can directly and in-
directly regulate mitochondrial biogenesis and function,
it remains to be confirmed whether testosterone can sig-
nificantly contribute to mitochondrial function.
Conclusions
Current studies show that mitochondria are important
for the initial step of steroidogenesis, and sex steroid
hormones (that is, estrogens) are capable of regulating
mitochondrial biogenesis and function. Dysregulation of
mitochondrial function and sex steroid hormone action
may compromise cellular integrity and lead to progres-
sive decline in tissue function. While the positive feed-
back loop of mitochondrial damage has been suggested
to partly contribute to aging and age-related phenotypes,
several questions still need to be addressed to validate
this theory. Nevertheless, research on this topic may po-
tentially provide insights into extending healthspan in
humans.
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